Related Information
-
News
- Making their mark: Louisville patent attorneys play key roles in invention process
- Biotechnology fuels drive for economic development
- Partners in Health Care: People to Watch in 2011
- Stites & Harbison names three new Members
- Update: Therapeutic Discovery Project Tax Credit Program - New Information Released May 21, 2010
- Mutant court case?
- Biotechnology companies receive R&D incentive from Health Care Reform, including tax credit and grant program for qualified therapeutic discovery projects
- Kentucky Competes Globally for Biotech Development Opportunities
- Events
- Case Studies
- Contacts
Stites and Harbison's Biotechnology/Life Sciences Law Group includes highly experienced and dedicated attorneys focused on intellectual property protection of all aspects of biotechnology and life sciences including genetic engineering, immunology, monoclonal antibodies, medical devices, diagnostics, therapeutics, genetic markers and pharmaceuticals.
The IP members of the Biotechnology/Life Sciences Law Group have extensive backgrounds in biotechnology and related fields, including work in research laboratories, experience with Patent Examination for the USPTO, and advanced degrees and/or technical experience in fields such as microbiology and immunology, biology, and pharmacology and cell biophysics.
The Biotechnology/Life Sciences Law Group represents a full range of clients in the biotechnological arts ranging from major companies and universities through a number of smaller start-up businesses.
In addition to patent prosecution, the Biotechnology/Life Sciences group counsels clients on all matters relating to domestic and international intellectual property issues, including issues relating to infringement, validity and freedom to operate. The group also has deep experienced in litigation and has handled cases involving biotechnological inventions in the federal and state courts.
Stites & Harbison distinguishes itself by having ongoing relationships with intellectual property firms throughout the world to provide its clients access to highly skilled international intellectual property counsel wherever and whenever needed.
In addition to offices in major Southeastern cities such as Atlanta, Louisville and Nashville, Stites & Harbison's strategically located office in Alexandria, Virginia, allows our attorneys to have in-person visits with Patent Examiners at the United States Patent & Trademark Office to discuss cases and advance our clients' positions.
Examples of recent biotechnology/life sciences patents issued with Stites & Harbison patent attorneys as counsel include:
- U.S. Patent No. 7,850,974, entitled "Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby" was drafted by Bill Schulman and was prosecuted by Bill Schulman, Terry Wright and Mandy Wilson Decker.
- U.S. Patent No. 7,858,388, entitled "MS based peptide and protein sequencing via reactions of lysine residues with peroxycarbonate compounds" was drafted and prosecuted by Richard Myers.
- U.S. Patent No. 7,329,542, entitled “Probes for Identifying Cancer-Specific Antigens” was prosecuted by Bill Schulman and Stephen Weyer. This patent relates to a method for producing an antibody-secreting cell probe (ASC-probe) against a cancer-specific antigen.
- U.S. Patent No. 7,196,220, entitled “Bone Targeting Compounds for Delivering Agents to the Bone for Interaction Therewith,” relating to the targeted delivery of agents to bone to affect treatments, such as treatment for osteoporosis or bone cancer. This patent was drafted and prosecuted by Mandy Wilson Decker.
- U.S. Patent No. 7,253,147, entitled "Modified Serum Albumin with Reduced Affinity for Nickel and Copper,” relating to the modified structure of human serum albumin at certain of its binding regions. This patent was drafted and prosecuted by Bill Schulman.
Other recent biotechnology/life sciences patents issued with Stites & Harbison patent attorneys as counsel include:
- U.S. Patent No. 7,892,754 — Hepatitis B virus pre-S1 derived synthetic polypeptides and uses thereof
- U.S. Patent No. 7,892,542 — Human anti-idiotypic antibody fragments that mimic HER-2/neu
- U.S. Patent No. 7,838,012 — S. aureus fibrinogen binding protein gene
- U.S. Patent No. 7,384,752 — DNA Encoding a Human Imidazolie Receptor and Ligand Binding Assay Employing Same
- U.S. Patent No. 7,381,793 — Extracellular Matrix-Binding Proteins from Staphylococcus Aureus
- U.S. Patent No. 7,375,132 — Compounds and Methods for Inhibiting Cellular Responses to Hypoxia
- U.S. Patent No. 7,364,738 — Monoclonal Antibodies to the CLFA Protein and Method of use in Treating Infections
- U.S. Patent No. 7,329,499 — Use of a Novel Human ULIP6/CRMP Protein in Diagnosis of Paraneoplastic Neurological Syndromes
- U.S. Patent No. 7,300,651 — Methods of Delaying Development of CEA-Associated Tumors using Anti-Idiotype Antibody 3H1
- U.S. Patent No. 7,229,780 — Monoclonal Antibody Against Ovarian Carcinoma
Biotechnology/Life Sciences is part of Stites & Harbison's larger, Intellectual Property and Technology (IPT) group, which includes more than 30 attorneys, 18 of whom are Registered U.S. Patent Attorneys, with expertise spanning all technical disciplines. The IPT group uses a team approach to provide clients with comprehensive intellectual property services. Our attorneys practice throughout the nation and the world in the areas of patents, trademarks, copyrights, trade secrets, licensing, computer software, e-commerce and intellectual property litigation.